Bimekizumab efficacy and safety through 4 years in moderate-to-severe plaque psoriasis: Long-term results from the BE SURE trial and BE BRIGHT open-label extension

Category Primary study
Conference56th Annual Scientific Meeting of the Australasian College of Dermatologists
Year 2024
This article has no abstract
Epistemonikos ID: 4e3698316ea4ac7cfa6749d18c12fbf0c324ffbc
First added on: Dec 20, 2025